SPP1 and metabolic dysfunction-associated steatotic liver disease: Current research points to associations between MASLD and elevated levels of uric acid, soluble CD163 (sCD163), interleukin-1 receptor antagonist (IL-1RA), osteopontin or osteonectin [41,42,43,44].